We are live on ! Find out more
CV

CapsoVision Inc

5.99 USD
+0.02
0.34%
At close Updated Sep 4, 4:00 PM EDT
1 day
0.34%
5 days
0.67%
1 month
-13.69%
3 months
-20.56%
6 months
15.41%
Year to date
-41.5%
1 year
58.47%
5 years
71.14%
10 years
71.14%
 

About: CapsoVision Inc is a commercial-stage medical technology enterprise that innovates, manufactures, and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal (GI) system. The company's core technology platform is an orally ingestible capsule including multiple cameras facilitating 360-degree imaging, light-emitting diodes for measurement, onboard memory storage, and battery life permitting recording and onboard storage of video images. CapsoVision's products consist of the on-market CapsoCam Plus, directed at the small intestines, and the in-development CapsoColon 3D, directed at the large intestines. Geographically, the company generates the majority of its revenue from the United States.

Employees: 99

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 0%
Neutral 100%
Negative 0%
Neutral
GlobeNewsWire
2 days ago
CapsoVision to Participate in Upcoming Investor Conferences
SARATOGA, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that Johnny Wang, President and Chief Executive Officer, David Garcia, Senior Vice President of Finance, and Doug Atkinson, Senior Vice President of Global Sales, plan to participate in the following upcoming investor conferences: H.C.
CapsoVision to Participate in Upcoming Investor Conferences
Neutral
Seeking Alpha
23 days ago
CapsoVision, Inc. (CV) Q2 2026 Earnings Call Transcript
CapsoVision, Inc. (CV) Q2 2026 Earnings Call Transcript
CapsoVision, Inc. (CV) Q2 2026 Earnings Call Transcript
Neutral
MarketBeat
23 days ago
CapsoVision Q2 Earnings Call Highlights
CapsoVision NASDAQ: CV reported second-quarter revenue growth as sales of its CapsoCam Plus capsule endoscopy system increased, while the company advanced its artificial intelligence software rollout and development programs for colon and upper gastrointestinal applications.
CapsoVision Q2 Earnings Call Highlights
Neutral
GlobeNewsWire
23 days ago
CapsoVision Reports Second Quarter 2026 Financial Results
SARATOGA, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today reported financial results and provided a business update for its second quarter ended June 30, 2026.
CapsoVision Reports Second Quarter 2026 Financial Results
Neutral
GlobeNewsWire
1 month ago
CapsoVision® Announces International Launch of AI Highlights
AI-assisted review feature designed to support physician review of small bowel capsule endoscopy studies using the CapsoCam Plus® system AI-assisted review feature designed to support physician review of small bowel capsule endoscopy studies using the CapsoCam Plus® system
CapsoVision® Announces International Launch of AI Highlights
Neutral
GlobeNewsWire
1 month ago
CapsoVision to Release Second Quarter 2026 Financial Results on August 13, 2026
SARATOGA, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that the Company will release second quarter 2026 financial results on Thursday, August 13, 2026, after the close of market.
CapsoVision to Release Second Quarter 2026 Financial Results on August 13, 2026
Neutral
GlobeNewsWire
2 months ago
CapsoVision Appoints Gastroenterology Leader David S. Shields, M.D.
SARATOGA, Calif., July 02, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (Nasdaq: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, announced the appointment of David S.
CapsoVision Appoints Gastroenterology Leader David S. Shields, M.D.
Positive
MarketBeat
3 months ago
CapsoVision Q1 Earnings Call Highlights
CapsoVision NASDAQ: CV reported steady first-quarter revenue and said it continues to advance artificial intelligence and capsule endoscopy programs aimed at expanding the use of its gastrointestinal imaging platform.
CapsoVision Q1 Earnings Call Highlights
Neutral
Seeking Alpha
3 months ago
CapsoVision, Inc. (CV) Q1 2026 Earnings Call Transcript
CapsoVision, Inc. (CV) Q1 2026 Earnings Call Transcript
CapsoVision, Inc. (CV) Q1 2026 Earnings Call Transcript
Neutral
GlobeNewsWire
3 months ago
CapsoVision Reports First Quarter 2026 Financial Results
SARATOGA, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today reported financial results for its first quarter ended March 31, 2026.
CapsoVision Reports First Quarter 2026 Financial Results
Price charts implemented using Lightweight Charts™